Panacea Biotech share price has zoomed 5% and is presently trading at Rs 469.2.
Meanwhile, the BSE HEALTHCARE index is at 43,781.9 (up 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are ASTER DM HEALTHCARE (up 2.9%) and Natco Pharma (up 1.9%).
POLY MEDICURE (down 2.9%) and FORTIS HEALTHCARE (down 1.3%) are among the top losers today.
Over the last one year, Panacea Biotech has moved up from Rs 160.1 to Rs 469.2, registering a gain of Rs 309.1 (up 193.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,654.9 to 43,781.9, registering a gain of 47.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 183.4%), SUVEN PHARMACEUTICALS (up 103.6%) and Glenmark Pharma (up 99.0%).
End of Year Sale: Save Rs 6,050 on our small cap research
The BSE Sensex is at 79,340.7 (down 0.6%).
The top losers among the BSE Sensex today are Indusind Bank (down 1.4%) and HDFC Bank (down 1.1%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,034.6 (down 0.4%). ONGC and HDFC LIFE INSURANCE are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,174.2 to 79,340.7, registering a gain of 13,166.5 points (up 19.9%).
Panacea Biotech net profit grew 156.8% YoY to Rs 47 million for the quarter ended September 2024, compared to a loss of Rs 83 million a year ago. Net sales rose 3.0% to Rs 1,474 million during the period as against Rs 1,430 million in July-September 2023.
For the year ended March 2024, Panacea Biotech reported 95.5% increase in net profit to Rs -15 million compared to net loss of Rs 337 million during FY23. Revenue of the company grew 21.6% to Rs 5,592 million during FY24.
The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -187.1.
Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 5%; BSE HEALTHCARE Index Up 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!